US FDA: Tentative Approval for Generic Lenacapavir Despite US Patent

• The FDA has granted tentative approval for a generic version of lenacapavir, a twice-a-year injectable HIV prevention drug.
• This `FDA tentative approval generic lenacapavir` enables its availability in 120 low- and middle-income countries at an estimated cost of $40 per person annually.
• The generic cannot be sold in the U.S. due to the existing patent for Gilead Sciences' brand-name Yeztugo, which costs $28,218 per year.
• Gilead Sciences facilitated global access by establishing royalty-free licensing agreements with six generic manufacturers for specific regions.
• The long-acting generic, developed by Dr. Reddy's Laboratories, is expected to significantly improve adherence and help combat the global HIV epidemic.

Lawyers advising pharmaceutical companies should note this 'tentative approval' pathway as a key mechanism for enabling global health initiatives while respecting intellectual property rights in the domestic market.

The U.S. Food and Drug Administration (FDA) has issued a tentative approval for a generic version of lenacapavir, a groundbreaking twice-a-year injectable medication designed to prevent HIV. This significant regulatory step paves the way for the drug's availability in 120 low- and middle-income nations, where it is projected to cost approximately $40 per person annually. This price point matches that of existing daily preventive pills, yet offers substantially greater convenience due to its infrequent administration.

The announcement, made by the generic manufacturer and several organizations instrumental in accelerating its development, underscores a global effort to expand access to critical HIV prevention tools. Clinical trials demonstrated lenacapavir's remarkable efficacy, nearly eliminating new infections among high-risk individuals. Experts, including Carmen Pérez Casas, Senior Strategy Lead & Pandemic Preparedness Head at Unitaid, highlight the challenge of daily medication adherence, noting that inconsistent use compromises protection against HIV. The long-acting nature of the lenacapavir shot addresses this barrier, offering renewed hope in the fight against the virus.

Despite this `FDA tentative approval generic lenacapavir`, the medication will not be available for sale in the United States. This restriction stems from the ongoing patent protection for the brand-name version, Yeztugo, manufactured by Gilead Sciences and approved last year. The U.S. list price for Gilead's Yeztugo, before insurance, stands at $28,218 per year, a cost Gilead officials indicate is comparable to other pre-exposure prophylaxis (PrEP) treatments.

The FDA's designation of "tentative approval" is a standard procedure for generic drugs while the original patent holder retains market exclusivity. This specific approval was granted under a long-established FDA practice aimed at guaranteeing the quality of HIV-related drugs supplied by the U.S. government to other countries. Such an approval by the U.S. FDA often expedites the regulatory processes in numerous other nations, facilitating quicker global deployment of essential medicines. Lawyers advising pharmaceutical companies should note this 'tentative approval' pathway as a key mechanism for enabling global health initiatives while respecting intellectual property rights in the domestic market.

Historically, Gilead Sciences was the sole provider of lenacapavir, and demand in low- and middle-income countries frequently outstripped supply. Recognizing the urgent need for broader access, Gilead established royalty-free licensing agreements last year with six generic manufacturers. These voluntary licenses specifically cover regions in sub-Saharan Africa, Asia, and Latin America, enabling local production and distribution. A Gilead spokesperson affirmed the company's commitment, stating, "We share the sense of urgency around expanding access to lenacapavir for HIV prevention," and expressed confidence in having "enabled the fastest and most sustainable path to expanding access for communities most affected by HIV."

The development of this `lenacapavir generic` was a collaborative undertaking, spearheaded by India-based `Dr. Reddy's Laboratories`. The project was brokered by a consortium including Unitaid, the Clinton Health Access Initiative, and Wits RHI, an African health research institute. These partners were united by the goal of accelerating the drug's development and ensuring its affordability, thereby maximizing its potential impact on global health.

The introduction of an affordable, high-quality generic lenacapavir represents a pivotal moment in the global battle against HIV and AIDS. Advocates believe this medication will significantly contribute to reducing new infections and associated deaths worldwide. According to the World Health Organization, 41 million people globally were living with HIV last year, with 570,000 succumbing to HIV-related causes. Carolyn Amole, Vice President of HIV, Hepatitis, and Tuberculosis for the Clinton Health Access Initiative, emphasized the potential to scale PrEP to 20 million individuals who need it, stating that achieving such levels could "actually begin to bring an end to the HIV epidemic."

While offering immense promise, the use of lenacapavir requires careful medical oversight. Common side effects include reactions at the injection site, headaches, and nausea. Crucially, individuals must undergo HIV testing before initiating the drug and prior to each subsequent injection, as cases of drug-resistant HIV have been observed in patients with undiagnosed infections. This underscores the importance of robust public health infrastructure alongside drug accessibility.

Lawyers advising pharmaceutical companies should note the FDA's 'tentative approval' pathway for generics of patent-protected drugs intended for export, and how voluntary licensing agreements, like those with Gilead, facilitate global access while maintaining US market exclusivity for the brand-name product.

Source: Original reporting via Associated Press